Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000725045 | SCV000333496 | uncertain significance | not provided | 2015-07-28 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000331953 | SCV000723611 | likely benign | not specified | 2017-10-13 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Labcorp Genetics |
RCV001446491 | SCV001649538 | likely benign | X-linked Emery-Dreifuss muscular dystrophy | 2022-10-13 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002365299 | SCV002661891 | likely benign | Cardiovascular phenotype | 2021-09-15 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Natera, |
RCV001833317 | SCV002084712 | likely benign | Emery-Dreifuss muscular dystrophy | 2020-09-14 | no assertion criteria provided | clinical testing |